219 related articles for article (PubMed ID: 30984972)
1. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.
Lin R; Yuan Y
Biostatistics; 2020 Oct; 21(4):807-824. PubMed ID: 30984972
[TBL] [Abstract][Full Text] [Related]
2. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
[TBL] [Abstract][Full Text] [Related]
3. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
5. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
6. Keyboard design for phase I drug-combination trials.
Pan H; Lin R; Zhou Y; Yuan Y
Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
[TBL] [Abstract][Full Text] [Related]
7. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials.
Zhou Y; Zhao Y; Cicconetti G; Mu Y; Yuan Y; Wang L; Penugonda S; Salman Z
Pharm Stat; 2023 Mar; 22(2):300-311. PubMed ID: 36333972
[TBL] [Abstract][Full Text] [Related]
8. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
[TBL] [Abstract][Full Text] [Related]
9. On the relative efficiency of model-assisted designs: a conditional approach.
Lin R; Yuan Y
J Biopharm Stat; 2019; 29(4):648-662. PubMed ID: 31258039
[TBL] [Abstract][Full Text] [Related]
10. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
11. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Takeda K; Xia Q; Liu S; Rong A
Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
[TBL] [Abstract][Full Text] [Related]
12. Incorporating historical information to improve phase I clinical trials.
Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS).
Pan H; Xie F; Liu P; Xia J; Ji Y
Clin Trials; 2014 Feb; 11(1):49-59. PubMed ID: 24137041
[TBL] [Abstract][Full Text] [Related]
14. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
15. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
Wages NA; Conaway MR
Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
[TBL] [Abstract][Full Text] [Related]
16. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
17. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.
Ji Y; Wang SJ
J Clin Oncol; 2013 May; 31(14):1785-91. PubMed ID: 23569307
[TBL] [Abstract][Full Text] [Related]
18. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
19. Nonparametric overdose control with late-onset toxicity in phase I clinical trials.
Lin R; Yin G
Biostatistics; 2017 Jan; 18(1):180-194. PubMed ID: 27549121
[TBL] [Abstract][Full Text] [Related]
20. Time-to-event calibration-free odds design: A robust efficient design for phase I trials with late-onset outcomes.
Jin H; Yin G
Pharm Stat; 2023; 22(5):773-783. PubMed ID: 37095681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]